Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma

The PRAME (EPR20330) Antibody evaluates PRAME protein expression from patients with suspected melanoma.Understanding if the PRAME protein is expressed helps enable more informed clinical decisions and may improve patient outcomes.The PRAME (EPR20330) Antibody is the latest addition to Roche ’s robust dermatology portfolio with more than 50 dermatology biomarkers designed to meet a broad range of diagnostic needs.Basel, 11 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma.Because the PRAME (PReferentially expressed Antigen in MElanoma) protein is expressed in most melanomas, the PRAME (EPR20330) Antibody* is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions. If PRAME expression is detected, this suggests that the lesion is malignant.“Every four minutes, one person dies from skin cancer. However, when detected early, localised melanoma is highly curable with a simple surgical excision,” said Thomas Schinecker, CEO of Roche Diagnostics. “Identifying this critical biomarker helps clinicians determine if their patient has mel anoma. We’re proud to add the PRAME assay to our already comprehensive test menu of dermatology biomarkers that help inform a patient’s diagnosis and treatment.”Melanoma is an aggressive skin cancer that originat...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news